The Group comprises a Point-of-Care Division in Oslo, a Laboratory Division in Dundee and local distribution subsidiaries in the UK (Axis-Shield UK), in Norway, Sweden, Denmark and Finland (Medinor), in Switzerland (Axis-Shield AG) and in Germany (Axis-Shield GmbH) and most of these companies also sell third-party products. We also have a representative office in China and a growing organisation in the USA which is primarily charged with accelerating the Afinion™ placement programme.
At the point of care, our products include the NycoCard® range and the Afinion™ system. In the laboratory sector we specialise in proprietary markers for the early diagnosis and management of critical illnesses such as cardiovascular and neurodegenerative diseases, rheumatoid arthritis and diabetes, where we are playing an increasingly leading role in the fight against the global diabetes epidemic, and the need to keep tight control over blood glucose levels to avoid serious clinical sequelae.
We have a special skill in adapting our markers to the automated analyser systems of the global IVD companies which dominate the hospital laboratory sector. The Company’s shares are traded on the main London and Oslo Stock Exchanges.